nodes	percent_of_prediction	percent_of_DWPC	metapath
Dextroamphetamine—CYP2D6—Arformoterol—chronic obstructive pulmonary disease	0.131	0.346	CbGbCtD
Dextroamphetamine—CYP2D6—Formoterol—chronic obstructive pulmonary disease	0.131	0.346	CbGbCtD
Dextroamphetamine—CYP2D6—Tiotropium—chronic obstructive pulmonary disease	0.117	0.308	CbGbCtD
Dextroamphetamine—Myocardial infarction—Arformoterol—chronic obstructive pulmonary disease	0.00223	0.00468	CcSEcCtD
Dextroamphetamine—Myocardial infarction—Formoterol—chronic obstructive pulmonary disease	0.00223	0.00468	CcSEcCtD
Dextroamphetamine—Urinary tract infection—Arformoterol—chronic obstructive pulmonary disease	0.00221	0.00464	CcSEcCtD
Dextroamphetamine—Urinary tract infection—Formoterol—chronic obstructive pulmonary disease	0.00221	0.00464	CcSEcCtD
Dextroamphetamine—Stevens-Johnson syndrome—Montelukast—chronic obstructive pulmonary disease	0.00221	0.00464	CcSEcCtD
Dextroamphetamine—Tremor—Aminophylline—chronic obstructive pulmonary disease	0.00219	0.00459	CcSEcCtD
Dextroamphetamine—Agitation—Aminophylline—chronic obstructive pulmonary disease	0.00215	0.0045	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Roflumilast—chronic obstructive pulmonary disease	0.00211	0.00442	CcSEcCtD
Dextroamphetamine—Urinary tract infection—Salbutamol—chronic obstructive pulmonary disease	0.00209	0.00438	CcSEcCtD
Dextroamphetamine—Palpitations—Aminophylline—chronic obstructive pulmonary disease	0.00207	0.00433	CcSEcCtD
Dextroamphetamine—Sweating—Salbutamol—chronic obstructive pulmonary disease	0.00206	0.00432	CcSEcCtD
Dextroamphetamine—Asthenia—Roflumilast—chronic obstructive pulmonary disease	0.00205	0.0043	CcSEcCtD
Dextroamphetamine—Convulsion—Aminophylline—chronic obstructive pulmonary disease	0.00203	0.00425	CcSEcCtD
Dextroamphetamine—Angioedema—Tiotropium—chronic obstructive pulmonary disease	0.00202	0.00422	CcSEcCtD
Dextroamphetamine—Anxiety—Aminophylline—chronic obstructive pulmonary disease	0.00199	0.00416	CcSEcCtD
Dextroamphetamine—Diarrhoea—Roflumilast—chronic obstructive pulmonary disease	0.00196	0.0041	CcSEcCtD
Dextroamphetamine—Palpitations—Tiotropium—chronic obstructive pulmonary disease	0.00195	0.00408	CcSEcCtD
Dextroamphetamine—Anaphylactic shock—Aminophylline—chronic obstructive pulmonary disease	0.00191	0.004	CcSEcCtD
Dextroamphetamine—Hypertension—Tiotropium—chronic obstructive pulmonary disease	0.0019	0.00399	CcSEcCtD
Dextroamphetamine—Infection—Aminophylline—chronic obstructive pulmonary disease	0.0019	0.00397	CcSEcCtD
Dextroamphetamine—Euphoric mood—Prednisolone—chronic obstructive pulmonary disease	0.0019	0.00397	CcSEcCtD
Dextroamphetamine—Erythema multiforme—Montelukast—chronic obstructive pulmonary disease	0.00189	0.00397	CcSEcCtD
Dextroamphetamine—Dizziness—Roflumilast—chronic obstructive pulmonary disease	0.00189	0.00397	CcSEcCtD
Dextroamphetamine—Chest pain—Tiotropium—chronic obstructive pulmonary disease	0.00188	0.00393	CcSEcCtD
Dextroamphetamine—Tachycardia—Aminophylline—chronic obstructive pulmonary disease	0.00186	0.0039	CcSEcCtD
Dextroamphetamine—Dry mouth—Tiotropium—chronic obstructive pulmonary disease	0.00184	0.00385	CcSEcCtD
Dextroamphetamine—Vomiting—Roflumilast—chronic obstructive pulmonary disease	0.00182	0.00381	CcSEcCtD
Dextroamphetamine—Anorexia—Aminophylline—chronic obstructive pulmonary disease	0.00182	0.00381	CcSEcCtD
Dextroamphetamine—Rash—Roflumilast—chronic obstructive pulmonary disease	0.00181	0.00378	CcSEcCtD
Dextroamphetamine—Dermatitis—Roflumilast—chronic obstructive pulmonary disease	0.0018	0.00378	CcSEcCtD
Dextroamphetamine—Headache—Roflumilast—chronic obstructive pulmonary disease	0.00179	0.00376	CcSEcCtD
Dextroamphetamine—Infection—Tiotropium—chronic obstructive pulmonary disease	0.00179	0.00375	CcSEcCtD
Dextroamphetamine—Viral infection—Prednisone—chronic obstructive pulmonary disease	0.00177	0.00372	CcSEcCtD
Dextroamphetamine—Tachycardia—Tiotropium—chronic obstructive pulmonary disease	0.00176	0.00368	CcSEcCtD
Dextroamphetamine—Tension—Arformoterol—chronic obstructive pulmonary disease	0.00175	0.00366	CcSEcCtD
Dextroamphetamine—Tension—Formoterol—chronic obstructive pulmonary disease	0.00175	0.00366	CcSEcCtD
Dextroamphetamine—Injury—Prednisolone—chronic obstructive pulmonary disease	0.00174	0.00365	CcSEcCtD
Dextroamphetamine—Nervousness—Formoterol—chronic obstructive pulmonary disease	0.00173	0.00362	CcSEcCtD
Dextroamphetamine—Nervousness—Arformoterol—chronic obstructive pulmonary disease	0.00173	0.00362	CcSEcCtD
Dextroamphetamine—Insomnia—Aminophylline—chronic obstructive pulmonary disease	0.00173	0.00362	CcSEcCtD
Dextroamphetamine—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.0017	0.00356	CcSEcCtD
Dextroamphetamine—Dyspepsia—Aminophylline—chronic obstructive pulmonary disease	0.00168	0.00352	CcSEcCtD
Dextroamphetamine—Tremor—Arformoterol—chronic obstructive pulmonary disease	0.00167	0.00349	CcSEcCtD
Dextroamphetamine—Tremor—Formoterol—chronic obstructive pulmonary disease	0.00167	0.00349	CcSEcCtD
Dextroamphetamine—Decreased appetite—Aminophylline—chronic obstructive pulmonary disease	0.00166	0.00348	CcSEcCtD
Dextroamphetamine—Tension—Salbutamol—chronic obstructive pulmonary disease	0.00165	0.00346	CcSEcCtD
Dextroamphetamine—Agitation—Arformoterol—chronic obstructive pulmonary disease	0.00164	0.00343	CcSEcCtD
Dextroamphetamine—Agitation—Formoterol—chronic obstructive pulmonary disease	0.00164	0.00343	CcSEcCtD
Dextroamphetamine—Tremor—Montelukast—chronic obstructive pulmonary disease	0.00163	0.00342	CcSEcCtD
Dextroamphetamine—Nervousness—Salbutamol—chronic obstructive pulmonary disease	0.00163	0.00342	CcSEcCtD
Dextroamphetamine—Insomnia—Tiotropium—chronic obstructive pulmonary disease	0.00163	0.00341	CcSEcCtD
Dextroamphetamine—Angioedema—Arformoterol—chronic obstructive pulmonary disease	0.00163	0.00341	CcSEcCtD
Dextroamphetamine—Angioedema—Formoterol—chronic obstructive pulmonary disease	0.00163	0.00341	CcSEcCtD
Dextroamphetamine—Agitation—Montelukast—chronic obstructive pulmonary disease	0.0016	0.00336	CcSEcCtD
Dextroamphetamine—Angioedema—Montelukast—chronic obstructive pulmonary disease	0.00159	0.00334	CcSEcCtD
Dextroamphetamine—Dyspepsia—Tiotropium—chronic obstructive pulmonary disease	0.00159	0.00332	CcSEcCtD
Dextroamphetamine—Affect lability—Prednisolone—chronic obstructive pulmonary disease	0.00158	0.0033	CcSEcCtD
Dextroamphetamine—Tremor—Salbutamol—chronic obstructive pulmonary disease	0.00158	0.0033	CcSEcCtD
Dextroamphetamine—Palpitations—Arformoterol—chronic obstructive pulmonary disease	0.00157	0.0033	CcSEcCtD
Dextroamphetamine—Palpitations—Formoterol—chronic obstructive pulmonary disease	0.00157	0.0033	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Aminophylline—chronic obstructive pulmonary disease	0.00156	0.00327	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.00155	0.00326	CcSEcCtD
Dextroamphetamine—Agitation—Salbutamol—chronic obstructive pulmonary disease	0.00155	0.00324	CcSEcCtD
Dextroamphetamine—Palpitations—Montelukast—chronic obstructive pulmonary disease	0.00154	0.00323	CcSEcCtD
Dextroamphetamine—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.00154	0.00323	CcSEcCtD
Dextroamphetamine—Hypertension—Formoterol—chronic obstructive pulmonary disease	0.00154	0.00322	CcSEcCtD
Dextroamphetamine—Hypertension—Arformoterol—chronic obstructive pulmonary disease	0.00154	0.00322	CcSEcCtD
Dextroamphetamine—Angioedema—Salbutamol—chronic obstructive pulmonary disease	0.00154	0.00322	CcSEcCtD
Dextroamphetamine—Ephedrine—ADRB2—chronic obstructive pulmonary disease	0.00153	0.096	CrCbGaD
Dextroamphetamine—Mood swings—Prednisolone—chronic obstructive pulmonary disease	0.00152	0.00318	CcSEcCtD
Dextroamphetamine—Urticaria—Aminophylline—chronic obstructive pulmonary disease	0.00152	0.00318	CcSEcCtD
Dextroamphetamine—Chest pain—Formoterol—chronic obstructive pulmonary disease	0.00152	0.00318	CcSEcCtD
Dextroamphetamine—Chest pain—Arformoterol—chronic obstructive pulmonary disease	0.00152	0.00318	CcSEcCtD
Dextroamphetamine—Convulsion—Montelukast—chronic obstructive pulmonary disease	0.00151	0.00317	CcSEcCtD
Dextroamphetamine—Anxiety—Formoterol—chronic obstructive pulmonary disease	0.00151	0.00316	CcSEcCtD
Dextroamphetamine—Anxiety—Arformoterol—chronic obstructive pulmonary disease	0.00151	0.00316	CcSEcCtD
Dextroamphetamine—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.00151	0.00316	CcSEcCtD
Dextroamphetamine—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	0.00151	0.00316	CcSEcCtD
Dextroamphetamine—Palpitations—Salbutamol—chronic obstructive pulmonary disease	0.00149	0.00311	CcSEcCtD
Dextroamphetamine—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.00148	0.00311	CcSEcCtD
Dextroamphetamine—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.00148	0.00311	CcSEcCtD
Dextroamphetamine—Anxiety—Montelukast—chronic obstructive pulmonary disease	0.00148	0.0031	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.00147	0.00308	CcSEcCtD
Dextroamphetamine—Anaphylactic shock—Arformoterol—chronic obstructive pulmonary disease	0.00145	0.00304	CcSEcCtD
Dextroamphetamine—Anaphylactic shock—Formoterol—chronic obstructive pulmonary disease	0.00145	0.00304	CcSEcCtD
Dextroamphetamine—Hypertension—Salbutamol—chronic obstructive pulmonary disease	0.00145	0.00304	CcSEcCtD
Dextroamphetamine—Infection—Formoterol—chronic obstructive pulmonary disease	0.00144	0.00302	CcSEcCtD
Dextroamphetamine—Infection—Arformoterol—chronic obstructive pulmonary disease	0.00144	0.00302	CcSEcCtD
Dextroamphetamine—Chest pain—Salbutamol—chronic obstructive pulmonary disease	0.00143	0.003	CcSEcCtD
Dextroamphetamine—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.00143	0.003	CcSEcCtD
Dextroamphetamine—Anxiety—Salbutamol—chronic obstructive pulmonary disease	0.00143	0.00299	CcSEcCtD
Dextroamphetamine—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.00142	0.00298	CcSEcCtD
Dextroamphetamine—Anaphylactic shock—Montelukast—chronic obstructive pulmonary disease	0.00142	0.00298	CcSEcCtD
Dextroamphetamine—Tachycardia—Formoterol—chronic obstructive pulmonary disease	0.00142	0.00297	CcSEcCtD
Dextroamphetamine—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	0.00142	0.00297	CcSEcCtD
Dextroamphetamine—Infection—Montelukast—chronic obstructive pulmonary disease	0.00141	0.00296	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.00141	0.00295	CcSEcCtD
Dextroamphetamine—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.0014	0.00293	CcSEcCtD
Dextroamphetamine—Euphoric mood—Prednisone—chronic obstructive pulmonary disease	0.00138	0.00289	CcSEcCtD
Dextroamphetamine—Phenylpropanolamine—ADRB2—chronic obstructive pulmonary disease	0.00137	0.0861	CrCbGaD
Dextroamphetamine—Anaphylactic shock—Salbutamol—chronic obstructive pulmonary disease	0.00137	0.00287	CcSEcCtD
Dextroamphetamine—Infection—Salbutamol—chronic obstructive pulmonary disease	0.00136	0.00286	CcSEcCtD
Dextroamphetamine—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.00134	0.00281	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.00133	0.00278	CcSEcCtD
Dextroamphetamine—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.00133	0.00278	CcSEcCtD
Dextroamphetamine—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.00131	0.00275	CcSEcCtD
Dextroamphetamine—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.00131	0.00275	CcSEcCtD
Dextroamphetamine—Pseudoephedrine—TNF—chronic obstructive pulmonary disease	0.00131	0.0821	CrCbGaD
Dextroamphetamine—Anorexia—Salbutamol—chronic obstructive pulmonary disease	0.00131	0.00274	CcSEcCtD
Dextroamphetamine—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.00131	0.00274	CcSEcCtD
Dextroamphetamine—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.0013	0.00271	CcSEcCtD
Dextroamphetamine—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.0013	0.00271	CcSEcCtD
Dextroamphetamine—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.00129	0.00271	CcSEcCtD
Dextroamphetamine—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.00129	0.00271	CcSEcCtD
Dextroamphetamine—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.00129	0.0027	CcSEcCtD
Dextroamphetamine—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.00128	0.00268	CcSEcCtD
Dextroamphetamine—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.00128	0.00268	CcSEcCtD
Dextroamphetamine—Injury—Prednisone—chronic obstructive pulmonary disease	0.00127	0.00265	CcSEcCtD
Dextroamphetamine—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.00127	0.00265	CcSEcCtD
Dextroamphetamine—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.00126	0.00265	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.00125	0.00263	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.00125	0.00263	CcSEcCtD
Dextroamphetamine—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.00125	0.00262	CcSEcCtD
Dextroamphetamine—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.00125	0.00262	CcSEcCtD
Dextroamphetamine—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.00125	0.00262	CcSEcCtD
Dextroamphetamine—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.00124	0.0026	CcSEcCtD
Dextroamphetamine—Constipation—Formoterol—chronic obstructive pulmonary disease	0.00124	0.0026	CcSEcCtD
Dextroamphetamine—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.00124	0.0026	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.00123	0.00257	CcSEcCtD
Dextroamphetamine—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.00123	0.00257	CcSEcCtD
Dextroamphetamine—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.00122	0.00256	CcSEcCtD
Dextroamphetamine—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.00122	0.00256	CcSEcCtD
Dextroamphetamine—Acute coronary syndrome—Prednisolone—chronic obstructive pulmonary disease	0.00122	0.00255	CcSEcCtD
Dextroamphetamine—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.00121	0.00254	CcSEcCtD
Dextroamphetamine—Myocardial infarction—Prednisolone—chronic obstructive pulmonary disease	0.00121	0.00253	CcSEcCtD
Dextroamphetamine—Tranylcypromine—CYP1A2—chronic obstructive pulmonary disease	0.00121	0.0757	CrCbGaD
Dextroamphetamine—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.00121	0.00253	CcSEcCtD
Dextroamphetamine—Rash—Aminophylline—chronic obstructive pulmonary disease	0.0012	0.00252	CcSEcCtD
Dextroamphetamine—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.0012	0.00252	CcSEcCtD
Dextroamphetamine—Headache—Aminophylline—chronic obstructive pulmonary disease	0.0012	0.00251	CcSEcCtD
Dextroamphetamine—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.00119	0.0025	CcSEcCtD
Dextroamphetamine—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.00119	0.00249	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.00119	0.00249	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.00119	0.00249	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.00118	0.00248	CcSEcCtD
Dextroamphetamine—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.00118	0.00248	CcSEcCtD
Dextroamphetamine—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.00117	0.00246	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.00116	0.00244	CcSEcCtD
Dextroamphetamine—Pseudoephedrine—ADRB2—chronic obstructive pulmonary disease	0.00116	0.0728	CrCbGaD
Dextroamphetamine—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.00115	0.00242	CcSEcCtD
Dextroamphetamine—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.00115	0.00242	CcSEcCtD
Dextroamphetamine—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.00115	0.00241	CcSEcCtD
Dextroamphetamine—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.00115	0.00241	CcSEcCtD
Dextroamphetamine—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.00115	0.00241	CcSEcCtD
Dextroamphetamine—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.00115	0.00241	CcSEcCtD
Dextroamphetamine—Affect lability—Prednisone—chronic obstructive pulmonary disease	0.00115	0.0024	CcSEcCtD
Dextroamphetamine—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.00114	0.0024	CcSEcCtD
Dextroamphetamine—Psychotic disorder—Prednisone—chronic obstructive pulmonary disease	0.00114	0.00238	CcSEcCtD
Dextroamphetamine—Phenylpropanolamine—CYP1A2—chronic obstructive pulmonary disease	0.00114	0.0712	CrCbGaD
Dextroamphetamine—Rash—Tiotropium—chronic obstructive pulmonary disease	0.00114	0.00238	CcSEcCtD
Dextroamphetamine—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.00113	0.00238	CcSEcCtD
Dextroamphetamine—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.00113	0.00238	CcSEcCtD
Dextroamphetamine—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.00113	0.00237	CcSEcCtD
Dextroamphetamine—Headache—Tiotropium—chronic obstructive pulmonary disease	0.00113	0.00236	CcSEcCtD
Dextroamphetamine—ADRA1B—Amine ligand-binding receptors—ADRB2—chronic obstructive pulmonary disease	0.00113	0.00882	CbGpPWpGaD
Dextroamphetamine—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.00113	0.00236	CcSEcCtD
Dextroamphetamine—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.00113	0.00236	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.00112	0.00235	CcSEcCtD
Dextroamphetamine—SLC6A2—NRF2 pathway—SOD3—chronic obstructive pulmonary disease	0.00111	0.00871	CbGpPWpGaD
Dextroamphetamine—Phentermine—SLC6A4—chronic obstructive pulmonary disease	0.00111	0.0697	CrCbGaD
Dextroamphetamine—Irritability—Prednisone—chronic obstructive pulmonary disease	0.00111	0.00233	CcSEcCtD
Dextroamphetamine—Mood swings—Prednisone—chronic obstructive pulmonary disease	0.0011	0.00231	CcSEcCtD
Dextroamphetamine—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.00109	0.00228	CcSEcCtD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—TRPV4—chronic obstructive pulmonary disease	0.00108	0.00849	CbGpPWpGaD
Dextroamphetamine—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.00108	0.00227	CcSEcCtD
Dextroamphetamine—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.00108	0.00227	CcSEcCtD
Dextroamphetamine—CYP2D6—Fatty Acid Omega Oxidation—CYP1A1—chronic obstructive pulmonary disease	0.00108	0.00844	CbGpPWpGaD
Dextroamphetamine—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.00107	0.00224	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.00107	0.00224	CcSEcCtD
Dextroamphetamine—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.00107	0.00224	CcSEcCtD
Dextroamphetamine—ADRA1A—Endothelin Pathways—EDN1—chronic obstructive pulmonary disease	0.00107	0.00833	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	0.00106	0.00833	CbGpPWpGaD
Dextroamphetamine—Pseudoephedrine—SLC6A4—chronic obstructive pulmonary disease	0.00105	0.0661	CrCbGaD
Dextroamphetamine—ADRA1B—Monoamine GPCRs—HTR2A—chronic obstructive pulmonary disease	0.00105	0.00821	CbGpPWpGaD
Dextroamphetamine—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.00105	0.0022	CcSEcCtD
Dextroamphetamine—SLC18A2—Transmission across Chemical Synapses—CHRNA3—chronic obstructive pulmonary disease	0.00105	0.0082	CbGpPWpGaD
Dextroamphetamine—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.00104	0.00218	CcSEcCtD
Dextroamphetamine—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.00104	0.00218	CcSEcCtD
Dextroamphetamine—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.00102	0.00214	CcSEcCtD
Dextroamphetamine—Phentermine—CYP1A2—chronic obstructive pulmonary disease	0.00101	0.0635	CrCbGaD
Dextroamphetamine—Benzyl alcohol—CYP1A1—chronic obstructive pulmonary disease	0.00101	0.0635	CrCbGaD
Dextroamphetamine—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.00101	0.00212	CcSEcCtD
Dextroamphetamine—SLC18A2—Dopaminergic Neurogenesis—TGFB1—chronic obstructive pulmonary disease	0.001	0.00786	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Amine ligand-binding receptors—ADRB2—chronic obstructive pulmonary disease	0.001	0.00784	CbGpPWpGaD
Dextroamphetamine—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000994	0.00208	CcSEcCtD
Dextroamphetamine—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000994	0.00208	CcSEcCtD
Dextroamphetamine—SLC6A3—NRF2 pathway—SOD3—chronic obstructive pulmonary disease	0.000986	0.00771	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Neuronal System—CHRNA5—chronic obstructive pulmonary disease	0.000985	0.00771	CbGpPWpGaD
Dextroamphetamine—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000985	0.00206	CcSEcCtD
Dextroamphetamine—Benzyl alcohol—CYP1A2—chronic obstructive pulmonary disease	0.000976	0.0612	CrCbGaD
Dextroamphetamine—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000974	0.00204	CcSEcCtD
Dextroamphetamine—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000961	0.00201	CcSEcCtD
Dextroamphetamine—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000961	0.00201	CcSEcCtD
Dextroamphetamine—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000941	0.00197	CcSEcCtD
Dextroamphetamine—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000939	0.00197	CcSEcCtD
Dextroamphetamine—Selegiline—CYP1A2—chronic obstructive pulmonary disease	0.000937	0.0587	CrCbGaD
Dextroamphetamine—ADRA1A—Monoamine GPCRs—HTR2A—chronic obstructive pulmonary disease	0.000932	0.00729	CbGpPWpGaD
Dextroamphetamine—Erectile dysfunction—Prednisone—chronic obstructive pulmonary disease	0.000926	0.00194	CcSEcCtD
Dextroamphetamine—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000924	0.00194	CcSEcCtD
Dextroamphetamine—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000924	0.00194	CcSEcCtD
Dextroamphetamine—CYP2D6—Melatonin metabolism and effects—CYP1A2—chronic obstructive pulmonary disease	0.000922	0.00721	CbGpPWpGaD
Dextroamphetamine—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000916	0.00192	CcSEcCtD
Dextroamphetamine—Rash—Formoterol—chronic obstructive pulmonary disease	0.000916	0.00192	CcSEcCtD
Dextroamphetamine—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000915	0.00192	CcSEcCtD
Dextroamphetamine—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000915	0.00192	CcSEcCtD
Dextroamphetamine—Headache—Formoterol—chronic obstructive pulmonary disease	0.00091	0.00191	CcSEcCtD
Dextroamphetamine—Headache—Arformoterol—chronic obstructive pulmonary disease	0.00091	0.00191	CcSEcCtD
Dextroamphetamine—Weight decreased—Prednisone—chronic obstructive pulmonary disease	0.00091	0.00191	CcSEcCtD
Dextroamphetamine—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000907	0.0019	CcSEcCtD
Dextroamphetamine—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000905	0.0019	CcSEcCtD
Dextroamphetamine—CYP2D6—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000902	0.00706	CbGpPWpGaD
Dextroamphetamine—Rash—Montelukast—chronic obstructive pulmonary disease	0.000898	0.00188	CcSEcCtD
Dextroamphetamine—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000897	0.00188	CcSEcCtD
Dextroamphetamine—Depression—Prednisone—chronic obstructive pulmonary disease	0.000894	0.00187	CcSEcCtD
Dextroamphetamine—Headache—Montelukast—chronic obstructive pulmonary disease	0.000892	0.00187	CcSEcCtD
Dextroamphetamine—Acute coronary syndrome—Prednisone—chronic obstructive pulmonary disease	0.000884	0.00185	CcSEcCtD
Dextroamphetamine—ADRA1B—Amine ligand-binding receptors—HTR2A—chronic obstructive pulmonary disease	0.000882	0.0069	CbGpPWpGaD
Dextroamphetamine—Angioedema—Prednisolone—chronic obstructive pulmonary disease	0.000881	0.00185	CcSEcCtD
Dextroamphetamine—Myocardial infarction—Prednisone—chronic obstructive pulmonary disease	0.000879	0.00184	CcSEcCtD
Dextroamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	0.000877	0.00686	CbGpPWpGaD
Dextroamphetamine—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000873	0.00183	CcSEcCtD
Dextroamphetamine—TAAR1—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	0.000872	0.00682	CbGpPWpGaD
Dextroamphetamine—ADRA1B—AMPK Signaling—ADIPOQ—chronic obstructive pulmonary disease	0.00087	0.00681	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000867	0.00679	CbGpPWpGaD
Dextroamphetamine—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000865	0.00181	CcSEcCtD
Dextroamphetamine—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000864	0.00181	CcSEcCtD
Dextroamphetamine—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000863	0.00181	CcSEcCtD
Dextroamphetamine—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000863	0.00181	CcSEcCtD
Dextroamphetamine—Headache—Salbutamol—chronic obstructive pulmonary disease	0.00086	0.0018	CcSEcCtD
Dextroamphetamine—Amphetamine—SLC6A4—chronic obstructive pulmonary disease	0.000855	0.0536	CrCbGaD
Dextroamphetamine—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000846	0.00177	CcSEcCtD
Dextroamphetamine—Convulsion—Prednisolone—chronic obstructive pulmonary disease	0.000836	0.00175	CcSEcCtD
Dextroamphetamine—Hypertension—Prednisolone—chronic obstructive pulmonary disease	0.000833	0.00174	CcSEcCtD
Dextroamphetamine—SLC6A2—Monoamine Transport—IL1B—chronic obstructive pulmonary disease	0.000826	0.00646	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—ATP2C2—chronic obstructive pulmonary disease	0.000819	0.00641	CbGpPWpGaD
Dextroamphetamine—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000815	0.00171	CcSEcCtD
Dextroamphetamine—SLC18A2—Neuronal System—CHRNA3—chronic obstructive pulmonary disease	0.000803	0.00628	CbGpPWpGaD
Dextroamphetamine—SLC6A2—NRF2 pathway—SERPINA1—chronic obstructive pulmonary disease	0.000793	0.00621	CbGpPWpGaD
Dextroamphetamine—Methamphetamine—SLC6A4—chronic obstructive pulmonary disease	0.000792	0.0497	CrCbGaD
Dextroamphetamine—Anaphylactic shock—Prednisolone—chronic obstructive pulmonary disease	0.000787	0.00165	CcSEcCtD
Dextroamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	0.000784	0.00613	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Amine ligand-binding receptors—HTR2A—chronic obstructive pulmonary disease	0.000783	0.00613	CbGpPWpGaD
Dextroamphetamine—ADRA1A—AMPK Signaling—ADIPOQ—chronic obstructive pulmonary disease	0.000773	0.00605	CbGpPWpGaD
Dextroamphetamine—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	0.000768	0.00161	CcSEcCtD
Dextroamphetamine—SLC6A3—Transmission across Chemical Synapses—CHRNA5—chronic obstructive pulmonary disease	0.000767	0.006	CbGpPWpGaD
Dextroamphetamine—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	0.000761	0.00159	CcSEcCtD
Dextroamphetamine—TAAR1—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	0.000746	0.00584	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Monoamine Transport—IL1B—chronic obstructive pulmonary disease	0.000732	0.00572	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—TRPV4—chronic obstructive pulmonary disease	0.00073	0.00571	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—ATP2C2—chronic obstructive pulmonary disease	0.000726	0.00568	CbGpPWpGaD
Dextroamphetamine—SLC6A2—NRF2 pathway—GCLC—chronic obstructive pulmonary disease	0.000725	0.00568	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Melatonin metabolism and effects—EDN1—chronic obstructive pulmonary disease	0.000715	0.00559	CbGpPWpGaD
Dextroamphetamine—Insomnia—Prednisolone—chronic obstructive pulmonary disease	0.000712	0.00149	CcSEcCtD
Dextroamphetamine—SLC6A3—NRF2 pathway—SERPINA1—chronic obstructive pulmonary disease	0.000703	0.0055	CbGpPWpGaD
Dextroamphetamine—SLC6A2—NRF2 pathway—TGFB2—chronic obstructive pulmonary disease	0.000688	0.00538	CbGpPWpGaD
Dextroamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	0.000686	0.00536	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	0.000678	0.0053	CbGpPWpGaD
Dextroamphetamine—SLC6A2—NRF2 pathway—SLC6A4—chronic obstructive pulmonary disease	0.000674	0.00528	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Melatonin metabolism and effects—CYP1A1—chronic obstructive pulmonary disease	0.00067	0.00524	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	0.000668	0.00522	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Endothelin Pathways—NOS3—chronic obstructive pulmonary disease	0.000649	0.00508	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—TRPV4—chronic obstructive pulmonary disease	0.000647	0.00506	CbGpPWpGaD
Dextroamphetamine—Agitation—Prednisone—chronic obstructive pulmonary disease	0.000644	0.00135	CcSEcCtD
Dextroamphetamine—SLC6A3—NRF2 pathway—GCLC—chronic obstructive pulmonary disease	0.000643	0.00503	CbGpPWpGaD
Dextroamphetamine—Angioedema—Prednisone—chronic obstructive pulmonary disease	0.00064	0.00134	CcSEcCtD
Dextroamphetamine—Urticaria—Prednisolone—chronic obstructive pulmonary disease	0.000625	0.00131	CcSEcCtD
Dextroamphetamine—SLC6A3—Transmission across Chemical Synapses—CHRNA3—chronic obstructive pulmonary disease	0.000625	0.00489	CbGpPWpGaD
Dextroamphetamine—SLC6A3—NRF2 pathway—TGFB2—chronic obstructive pulmonary disease	0.000609	0.00477	CbGpPWpGaD
Dextroamphetamine—Convulsion—Prednisone—chronic obstructive pulmonary disease	0.000607	0.00127	CcSEcCtD
Dextroamphetamine—Hypertension—Prednisone—chronic obstructive pulmonary disease	0.000605	0.00127	CcSEcCtD
Dextroamphetamine—TAAR1—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	0.000602	0.00471	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Monoamine Transport—TNF—chronic obstructive pulmonary disease	0.000599	0.00469	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Dopaminergic Neurogenesis—TGFB1—chronic obstructive pulmonary disease	0.000599	0.00468	CbGpPWpGaD
Dextroamphetamine—SLC6A3—NRF2 pathway—SLC6A4—chronic obstructive pulmonary disease	0.000597	0.00467	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	0.000597	0.00467	CbGpPWpGaD
Dextroamphetamine—Anxiety—Prednisone—chronic obstructive pulmonary disease	0.000595	0.00125	CcSEcCtD
Dextroamphetamine—SLC6A3—Neuronal System—CHRNA5—chronic obstructive pulmonary disease	0.000587	0.0046	CbGpPWpGaD
Dextroamphetamine—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	0.00058	0.00121	CcSEcCtD
Dextroamphetamine—Anaphylactic shock—Prednisone—chronic obstructive pulmonary disease	0.000572	0.0012	CcSEcCtD
Dextroamphetamine—Infection—Prednisone—chronic obstructive pulmonary disease	0.000568	0.00119	CcSEcCtD
Dextroamphetamine—Tachycardia—Prednisone—chronic obstructive pulmonary disease	0.000558	0.00117	CcSEcCtD
Dextroamphetamine—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	0.000553	0.00116	CcSEcCtD
Dextroamphetamine—TAAR1—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	0.000546	0.00427	CbGpPWpGaD
Dextroamphetamine—Anorexia—Prednisone—chronic obstructive pulmonary disease	0.000545	0.00114	CcSEcCtD
Dextroamphetamine—ADRA1B—AMPK Signaling—LEP—chronic obstructive pulmonary disease	0.000541	0.00423	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Monoamine Transport—TNF—chronic obstructive pulmonary disease	0.000531	0.00415	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	0.000528	0.00413	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000527	0.00412	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	0.000522	0.00408	CbGpPWpGaD
Dextroamphetamine—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.00052	0.00109	CcSEcCtD
Dextroamphetamine—Insomnia—Prednisone—chronic obstructive pulmonary disease	0.000517	0.00108	CcSEcCtD
Dextroamphetamine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000515	0.00403	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000509	0.00398	CbGpPWpGaD
Dextroamphetamine—SLC6A2—NRF2 pathway—GSTP1—chronic obstructive pulmonary disease	0.000509	0.00398	CbGpPWpGaD
Dextroamphetamine—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	0.000503	0.00105	CcSEcCtD
Dextroamphetamine—SLC6A2—NRF2 pathway—HMOX1—chronic obstructive pulmonary disease	0.000502	0.00392	CbGpPWpGaD
Dextroamphetamine—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	0.000497	0.00104	CcSEcCtD
Dextroamphetamine—Rash—Prednisolone—chronic obstructive pulmonary disease	0.000496	0.00104	CcSEcCtD
Dextroamphetamine—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	0.000496	0.00104	CcSEcCtD
Dextroamphetamine—Fatigue—Prednisone—chronic obstructive pulmonary disease	0.000493	0.00103	CcSEcCtD
Dextroamphetamine—Headache—Prednisolone—chronic obstructive pulmonary disease	0.000493	0.00103	CcSEcCtD
Dextroamphetamine—Constipation—Prednisone—chronic obstructive pulmonary disease	0.000489	0.00102	CcSEcCtD
Dextroamphetamine—Nateglinide—ALB—chronic obstructive pulmonary disease	0.000484	0.0303	CrCbGaD
Dextroamphetamine—ADRA1A—AMPK Signaling—LEP—chronic obstructive pulmonary disease	0.00048	0.00376	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Neuronal System—CHRNA3—chronic obstructive pulmonary disease	0.000479	0.00375	CbGpPWpGaD
Dextroamphetamine—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	0.000468	0.00098	CcSEcCtD
Dextroamphetamine—Nausea—Prednisolone—chronic obstructive pulmonary disease	0.000468	0.000979	CcSEcCtD
Dextroamphetamine—SLC6A2—NRF2 pathway—GSTM1—chronic obstructive pulmonary disease	0.000467	0.00366	CbGpPWpGaD
Dextroamphetamine—Urticaria—Prednisone—chronic obstructive pulmonary disease	0.000454	0.000952	CcSEcCtD
Dextroamphetamine—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	0.000452	0.000947	CcSEcCtD
Dextroamphetamine—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	0.000452	0.000947	CcSEcCtD
Dextroamphetamine—SLC6A3—NRF2 pathway—GSTP1—chronic obstructive pulmonary disease	0.000451	0.00353	CbGpPWpGaD
Dextroamphetamine—SLC6A3—NRF2 pathway—HMOX1—chronic obstructive pulmonary disease	0.000444	0.00348	CbGpPWpGaD
Dextroamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	0.000424	0.00331	CbGpPWpGaD
Dextroamphetamine—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	0.000421	0.000883	CcSEcCtD
Dextroamphetamine—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000418	0.00327	CbGpPWpGaD
Dextroamphetamine—SLC6A3—NRF2 pathway—GSTM1—chronic obstructive pulmonary disease	0.000414	0.00324	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—CXCR2—chronic obstructive pulmonary disease	0.000413	0.00323	CbGpPWpGaD
Dextroamphetamine—Asthenia—Prednisone—chronic obstructive pulmonary disease	0.00041	0.00086	CcSEcCtD
Dextroamphetamine—ADRA1B—Calcium Regulation in the Cardiac Cell—ADRB2—chronic obstructive pulmonary disease	0.000402	0.00314	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	0.0004	0.00313	CbGpPWpGaD
Dextroamphetamine—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	0.000391	0.00082	CcSEcCtD
Dextroamphetamine—ADRA1B—LPA receptor mediated events—CXCL8—chronic obstructive pulmonary disease	0.000381	0.00298	CbGpPWpGaD
Dextroamphetamine—Dizziness—Prednisone—chronic obstructive pulmonary disease	0.000378	0.000792	CcSEcCtD
Dextroamphetamine—TAAR1—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	0.000377	0.00295	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000375	0.00293	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.00037	0.00289	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCRs, Class A Rhodopsin-like—CXCR2—chronic obstructive pulmonary disease	0.000367	0.00287	CbGpPWpGaD
Dextroamphetamine—Vomiting—Prednisone—chronic obstructive pulmonary disease	0.000364	0.000762	CcSEcCtD
Dextroamphetamine—Rash—Prednisone—chronic obstructive pulmonary disease	0.000361	0.000755	CcSEcCtD
Dextroamphetamine—Dermatitis—Prednisone—chronic obstructive pulmonary disease	0.00036	0.000755	CcSEcCtD
Dextroamphetamine—Headache—Prednisone—chronic obstructive pulmonary disease	0.000358	0.000751	CcSEcCtD
Dextroamphetamine—ADRA1A—Calcium Regulation in the Cardiac Cell—ADRB2—chronic obstructive pulmonary disease	0.000357	0.00279	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	0.000354	0.00277	CbGpPWpGaD
Dextroamphetamine—ADRA1B—LPA receptor mediated events—MMP9—chronic obstructive pulmonary disease	0.000345	0.0027	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	0.000343	0.00268	CbGpPWpGaD
Dextroamphetamine—Nausea—Prednisone—chronic obstructive pulmonary disease	0.00034	0.000712	CcSEcCtD
Dextroamphetamine—TAAR1—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	0.000337	0.00264	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	0.000323	0.00252	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	0.000323	0.00252	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	0.000314	0.00246	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	0.000306	0.0024	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.000304	0.00238	CbGpPWpGaD
Dextroamphetamine—ADRA1B—G alpha (q) signalling events—EDN1—chronic obstructive pulmonary disease	0.000299	0.00234	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	0.000295	0.00231	CbGpPWpGaD
Dextroamphetamine—SLC18A2—SLC-mediated transmembrane transport—ALB—chronic obstructive pulmonary disease	0.000282	0.00221	CbGpPWpGaD
Dextroamphetamine—ADRA1B—LPA receptor mediated events—EGFR—chronic obstructive pulmonary disease	0.000279	0.00218	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	0.000269	0.00211	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	0.000268	0.0021	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—chronic obstructive pulmonary disease	0.000268	0.00209	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.000267	0.00209	CbGpPWpGaD
Dextroamphetamine—ADRA1A—G alpha (q) signalling events—EDN1—chronic obstructive pulmonary disease	0.000266	0.00208	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.000264	0.00207	CbGpPWpGaD
Dextroamphetamine—ADRA1B—G alpha (q) signalling events—HTR2A—chronic obstructive pulmonary disease	0.000262	0.00205	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	0.000259	0.00203	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	0.000239	0.00187	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	0.000239	0.00187	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—chronic obstructive pulmonary disease	0.000238	0.00186	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	0.000236	0.00185	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—chronic obstructive pulmonary disease	0.000234	0.00183	CbGpPWpGaD
Dextroamphetamine—ADRA1A—G alpha (q) signalling events—HTR2A—chronic obstructive pulmonary disease	0.000233	0.00182	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	0.00023	0.0018	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	0.000222	0.00174	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	0.000222	0.00174	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	0.000221	0.00173	CbGpPWpGaD
Dextroamphetamine—ADRA1B—AMPK Signaling—TP53—chronic obstructive pulmonary disease	0.00022	0.00172	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—KL—chronic obstructive pulmonary disease	0.000219	0.00172	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	0.000219	0.00171	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—chronic obstructive pulmonary disease	0.000208	0.00163	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	0.000202	0.00158	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	0.000202	0.00158	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	0.000198	0.00155	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	0.000197	0.00154	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	0.000196	0.00153	CbGpPWpGaD
Dextroamphetamine—ADRA1A—AMPK Signaling—TP53—chronic obstructive pulmonary disease	0.000196	0.00153	CbGpPWpGaD
Dextroamphetamine—SLC6A2—NRF2 pathway—TGFB1—chronic obstructive pulmonary disease	0.000191	0.00149	CbGpPWpGaD
Dextroamphetamine—SLC6A2—SLC-mediated transmembrane transport—ALB—chronic obstructive pulmonary disease	0.00019	0.00149	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	0.000189	0.00148	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	0.000185	0.00145	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	0.000183	0.00143	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	0.000182	0.00143	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	0.000181	0.00142	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	0.00018	0.00141	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	0.000176	0.00138	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	0.000173	0.00136	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	0.000171	0.00134	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	0.00017	0.00133	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	0.000169	0.00132	CbGpPWpGaD
Dextroamphetamine—SLC6A3—NRF2 pathway—TGFB1—chronic obstructive pulmonary disease	0.000169	0.00132	CbGpPWpGaD
Dextroamphetamine—SLC6A3—SLC-mediated transmembrane transport—ALB—chronic obstructive pulmonary disease	0.000168	0.00132	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	0.000168	0.00131	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	0.000168	0.00131	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	0.000166	0.00129	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	0.000164	0.00129	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	0.000161	0.00126	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	0.000161	0.00126	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	0.000159	0.00124	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	0.000158	0.00124	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	0.000154	0.00121	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	0.000152	0.00119	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	0.000152	0.00119	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	0.000151	0.00118	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	0.00015	0.00117	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—LEP—chronic obstructive pulmonary disease	0.000147	0.00115	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	0.000143	0.00112	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	0.000142	0.00111	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	0.000138	0.00108	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	0.000135	0.00106	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	0.000134	0.00105	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	0.000134	0.00105	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	0.000132	0.00103	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—APIP—chronic obstructive pulmonary disease	0.00013	0.00102	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	0.000123	0.00096	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	0.000121	0.000947	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	0.000119	0.000929	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	0.000117	0.000918	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	0.000115	0.000903	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	0.00011	0.000862	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	0.000107	0.000838	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—chronic obstructive pulmonary disease	0.000106	0.000827	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	0.000101	0.000792	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	9.78e-05	0.000765	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	9.65e-05	0.000755	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	9.55e-05	0.000747	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	9.52e-05	0.000745	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—chronic obstructive pulmonary disease	9.39e-05	0.000735	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	9.3e-05	0.000727	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	9e-05	0.000704	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	8.84e-05	0.000692	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	8.67e-05	0.000678	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	8.6e-05	0.000672	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	8.55e-05	0.000669	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	8.53e-05	0.000667	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	8.48e-05	0.000663	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—GC—chronic obstructive pulmonary disease	8.36e-05	0.000654	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	8.16e-05	0.000639	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	8.16e-05	0.000638	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	8.13e-05	0.000636	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	7.94e-05	0.000621	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	7.77e-05	0.000608	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	7.75e-05	0.000606	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	7.7e-05	0.000602	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	7.58e-05	0.000593	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	7.46e-05	0.000584	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	7.29e-05	0.00057	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	7.25e-05	0.000567	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	7.25e-05	0.000567	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	7.22e-05	0.000565	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	7.15e-05	0.000559	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	6.88e-05	0.000538	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	6.78e-05	0.00053	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	6.63e-05	0.000519	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	6.02e-05	0.000471	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	6e-05	0.000469	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	5.97e-05	0.000467	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—KL—chronic obstructive pulmonary disease	5.55e-05	0.000434	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	5.49e-05	0.00043	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	5.3e-05	0.000415	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	5.12e-05	0.000401	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—KL—chronic obstructive pulmonary disease	4.93e-05	0.000386	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	4.61e-05	0.000361	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	4.58e-05	0.000358	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—GSTT1—chronic obstructive pulmonary disease	4.57e-05	0.000357	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	4.55e-05	0.000356	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—GCLC—chronic obstructive pulmonary disease	4.52e-05	0.000353	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	4.19e-05	0.000328	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	4.16e-05	0.000325	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CTGF—chronic obstructive pulmonary disease	4.12e-05	0.000322	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	4.1e-05	0.00032	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	4.07e-05	0.000318	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	4e-05	0.000313	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CYP1A2—chronic obstructive pulmonary disease	3.8e-05	0.000297	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—LEP—chronic obstructive pulmonary disease	3.72e-05	0.000291	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	3.72e-05	0.000291	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	3.7e-05	0.000289	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	3.56e-05	0.000278	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—LEP—chronic obstructive pulmonary disease	3.31e-05	0.000259	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—GSTP1—chronic obstructive pulmonary disease	3.17e-05	0.000248	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—HMOX1—chronic obstructive pulmonary disease	3.12e-05	0.000244	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	3.06e-05	0.000239	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	2.92e-05	0.000229	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—GSTM1—chronic obstructive pulmonary disease	2.91e-05	0.000228	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	2.79e-05	0.000218	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	2.76e-05	0.000216	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	2.72e-05	0.000213	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	2.59e-05	0.000203	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	2.48e-05	0.000194	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	2.47e-05	0.000194	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	2.35e-05	0.000184	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	2.24e-05	0.000175	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	2.2e-05	0.000172	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	2.09e-05	0.000163	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.01e-05	0.000157	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	1.99e-05	0.000155	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ALB—chronic obstructive pulmonary disease	1.87e-05	0.000147	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	1.84e-05	0.000144	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	1.81e-05	0.000141	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—NOS3—chronic obstructive pulmonary disease	1.79e-05	0.00014	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	1.78e-05	0.00014	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	1.64e-05	0.000128	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	1.61e-05	0.000126	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.52e-05	0.000119	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.39e-05	0.000109	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.35e-05	0.000105	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.23e-05	9.66e-05	CbGpPWpGaD
